Day: March 28, 2024

Chief People Officer, Amy Hanlon-Rodemich to leave Nokia

Written by Customer Service on March 28, 2024. Posted in Public Companies.

Nokia CorporationStock Exchange Release28 March 2024 at 16:15 EET Chief People Officer, Amy Hanlon-Rodemich to leave Nokia Espoo, Finland – Nokia today announces that its Chief People Officer, Amy Hanlon-Rodemich, will leave the company and step down from its Group Leadership Team. A recruitment process will begin immediately for her successor and Amy will retain an advisory role during her notice period. Amy joined Nokia in 2022 and has been key to renewing the company’s people services and employee experience. “This has been a difficult decision for me to take. I’ve enjoyed my time at Nokia and am looking forward to the next chapter in my career. I wish everyone at Nokia continued success,” commented Amy. “I would like to thank Amy for her contributions to Nokia and leadership of the People organisation. I wish her all the best with...

Highest Performances Announces Acquisition of an AI Humanoid Robot Hardware Manufacturer

Written by Customer Service on March 28, 2024. Posted in Mergers And Acquisitions.

GUANGZHOU, China, March 28, 2024 (GLOBE NEWSWIRE) — Highest Performances Holdings Inc. (NASDAQ: HPH) (“HPH” or the “Company”), a leading third-party wealth management services provider in China, today announces that, on March 27, 2024, the Company entered into a second supplementary agreement (the “Supplementary Agreement II”) to the strategic framework agreement previously entered into with Singapore White Group Pte. Ltd. (“White Group”). Pursuant to the Supplementary Agreement II, the Company will acquire 77.5% of the equity interests in Singapore White Lingjun Pte. Ltd. (“Singapore Lingjun”), a wholly-owned subsidiary of White Group. In exchange, the Company will issue an aggregate of 20,758,929 American Depositary Shares (“ADSs”), equivalent to 31,138,394 ordinary shares of the Company, to White Group. The shares consideration...

Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting

Written by Customer Service on March 28, 2024. Posted in Public Companies.

Presentation will address the Company’s clinical data in Parkinson’s disease CAPE CANAVERAL, Fla., March 28, 2024 (GLOBE NEWSWIRE) — Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its UB-312 program in Parkinson’s disease at the Annual Academy of Neurology (AAN) 2024 Annual Meeting, taking place April 13-18, 2024 virtually and in Denver, Colorado. Presentation details are as follows:Oral PresentationSession: ES2 – Emerging ScienceTitle: Evidence of Target Engagement in a Phase 1 Clinical Trial of UB-312 in Parkinson’s DiseasePresenter: Jean-Cosme Dodart, Ph.D., CSO at VaxxinityDate & Time: April 16, 2024 at 5:54 pm MT The AAN Annual Meeting is the largest gathering of neurologists and neuroscience professionals...

Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update

Written by Customer Service on March 28, 2024. Posted in Earnings Releases And Operating Results.

Advanced OTX-2002 in MYCHELANGELO™ I trial; initial cohorts demonstrated encouraging disease control rate in late-stage HCC patients Established a research collaboration with Novo Nordisk to develop an epigenomic controller for obesity, expanding the pipeline into the cardiometabolic space Announced strategic prioritization to focus resources on potential near-term value drivers, support long-term growth, and extend cash runway into Q1 2025CAMBRIDGE, Mass., March 28, 2024 (GLOBE NEWSWIRE) — Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced financial results for the fourth quarter and full year ended December 31, 2023, and a strategic prioritization initiative to focus resources...

BOS Reports Financial Results for the Fourth Quarter and the Year 2023

Written by Customer Service on March 28, 2024. Posted in Earnings Releases And Operating Results.

Exceeds the projections for 2023 and positive outlook for year 2024 RISHON LE ZION, Israel, March 28, 2024 (GLOBE NEWSWIRE) — BOS Better Online Solutions Ltd. (“BOS” or the “Company”) (NASDAQ: BOSC) reported its financial results for the fourth quarter and the year 2023. Year 2023 Financial Highlights:Revenues grew by 6.5% to $44.2 million from $41.5 million in the year 2022 ; Operating profit increased to $2.5 million from $1.9 million in the year 2022; EBITDA amounted to $3.06 million compared to $2.4 million in the year 2022. Financial expenses decreased to $441,000 from $647,000 in the year 2022. Net income amounted to $2.01 million or $0.35 per basic share compared to $1.28 million or $0.23 per basic share in the year 2022.Fourth Quarter 2023 Financial Highlights:Revenues reduced by 3.5% to $10.9...

Janover Reports Fiscal 2023 Financial Results and Provides Business Update

Written by Customer Service on March 28, 2024. Posted in Earnings Releases And Operating Results.

Reports 54% Increase in Revenue Per Transaction in 2023 Revenue from Small Business Transactions Grows More Than 100% for Second Consecutive Year BOCA RATON, Fla., March 28, 2024 (GLOBE NEWSWIRE) — Janover Inc. (Nasdaq: JNVR) (“Janover” or the “Company”), an AI-enabled platform for commercial real estate transactions, today provided a business update, and announced its financial results for the year-ended December 31, 2023. Key FinancialsRevenue per transaction increased 54% year-over-year for the year-ended December 31, 2023; Revenue from Small Business transactions, which includes Small Business Administration (SBA), increased more than 100%, for the second consecutive year; Completed IPO in July 2023 and raised over $5.0 million in all common stock; Generated revenue of $2.0 million in 2023, versus $2.2 million in 2022, despite...

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results

Written by Customer Service on March 28, 2024. Posted in Earnings Releases And Operating Results.

First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction (PH-HFpEF) Expansion of U.S. Intellectual Property Covering the Use of Levosimendan for the Treatment of PH-HFpEF and for Use in Combination with Other Cardiovascular Therapies The Company Secured Global Commercial Rights to Levosimendan for the Treatment of PH-HFpEF The Company will host a KOL Event, “LEVEL Setting: The Scientific Rationale for Levosimendan as the First Treatment for PH-HFpEF and the Ongoing Phase 3 LEVEL Study,” on Thursday, April 18th at 10:00 am ET Link to Register CHAPEL HILL, N.C., March 28, 2024 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying,...

Additional Drill Results Highlighted by Hole D-380 in Block 6 at Oko West, Intersecting 39.7 m Grading 5.27 g/t Au Including 2.8 m @ 14.18 g/t Au and 13.0 m Grading 10.50 g/t Au

Written by Customer Service on March 28, 2024. Posted in Public Companies.

LONGUEUIL, Quebec, March 28, 2024 (GLOBE NEWSWIRE) — Reunion Gold Corporation (TSXV: RGD; OTCQX: RGDFF) (the “Company”) is pleased to announce additional drill results from its ongoing infill and step out drill program at the Kairuni zone on its Oko West project in Guyana. Hole D-380, which is located in Block 6 (see Table 1 and Figure 1) intersected 39.7 meters (“m”) @ 5.27 grams per tonne of gold (“g/t Au”) from 152.3 m downhole (using a 0.3 g/t Au cutoff), including 3.8 m @ 14.18 g/t Au and 13.0 m @ 10.50 g/t Au (using 1.5 g/t Au cutoffs). The results from Hole D-380 are encouraging as they indicate the potential for additional high-grade mineralized shoots to be defined in areas of existing wider drill spacing where the current infill continues. Downdip from D-380 and also within Block 6, drill hole D-392 intersected 70.3 m...

Form 8.3 – [abrdn EUROPEAN LOGISTICS INCOME PLC – 27 03 2024] – (CGWL)

Written by Customer Service on March 28, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree abrdn EUROPEAN LOGISTICS INCOME PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date...

Abaxx Announces Closing of C$18,687,500 Bought Deal Financing Including Full Exercise of Over-Allotment Option

Written by Customer Service on March 28, 2024. Posted in Public Companies.

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, March 28, 2024 (GLOBE NEWSWIRE) — Abaxx Technologies Inc. (CBOE CA:ABXX) (“Abaxx” or the “Company”), a financial software and market infrastructure company, majority shareholder of Abaxx Singapore Pte Ltd., the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing”), and producer of the SmarterMarkets™ Podcast, is pleased to announce that it has closed its previously announced bought deal financing (the “Offering”). The Company issued a total of 1,437,500 common shares (the “Common Shares”) on a bought deal basis at an offering price of C$13.00 per Common Share (the “Offering Price”), which includes 187,500 Common Shares issued pursuant to the exercise of an over-allotment...

Day: March 28, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice